advertisement

Malaria

17 January 2011

GSK malaria vaccine long-lasting protection

An experimental malaria vaccine from GlaxoSmithKline provides African children with long-lasting protection, though its effectiveness declines slightly over time.

An experimental malaria vaccine from GlaxoSmithKline provides African children with long-lasting protection, though its effectiveness declines slightly over time, according to trial data published.

The World Health Organisation's (WHO) latest malaria report found progress against the disease has been made over the past decade, with deaths estimated to have dropped to 781,000 in 2009 from nearly a million in 2000.

 

Read Health24’s Comments Policy

Comment on this story
0 comments
Comments have been closed for this article.